Product
BBI-355
Name
BBI-355
1 clinical trial
11 indications
Indication
Lung CancerIndication
Lung AdenocarcinomaIndication
Head and Neck Squamous Cell CarcinomaIndication
Esophageal cancerIndication
Stomach CancerIndication
Breast CancerIndication
Bladder CancerIndication
Ovarian CancerIndication
Endometrial CancerIndication
LiposarcomaIndication
NSCLCClinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene AmplificationsStatus: Recruiting, Estimated PCD: 2026-09-30